ThermoGenesis Holdings, Inc. (THMO)

Market Cap	4.39M
Revenue (ttm)	10.23M
Net Income (ttm)	-10.49M
Shares Out	1.04M
EPS (ttm)	-30.60
PE Ratio	n/a
Forward PE	2.28
Dividend	n/a
Ex-Dividend Date	n/a

Volume	243,082
Open	4.05
Previous Close	3.95
Day's Range	3.96 - 4.54
52-Week Range	2.67 - 40.95
Beta	2.54
Analysts	Buy
Price Target	45.90 (+985.11%)
Earnings Date	Mar 27, 2023

About THMO

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP II Automated Cell Separation System, an automa...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1986
• Employees: 39
• Stock Exchange: NASDAQ
• Ticker Symbol: THMO

Financial Performance

In 2021, THMO's revenue was $9.29 million, a decrease of -4.62% compared to the previous year's $9.74 million. Losses were -$11.38 million, -30.41% less than in 2020.

Analyst Forecast

According to 7 analysts, the average rating for THMO stock is "Buy." The 12-month stock price forecast is $45.9, which is an increase of 985.11% from the latest price.

Price Target

$45.9

(985.11% upside)

Analyst Consensus: Buy